The study, led by Hye Ju Yeo and Ha Lim Kim of Pusan National University Yangsan Hospital in South Korea, together with colleagues including Woo Hyun Cho, examined 1,107 adults with sepsis who had undergone abdominal CT imaging as part of their clinical care. Rather than relying on height and weight, the team deployed an automated segmentation pipeline built on the nnU-Net framework, a self-configuring deep learning architecture that has become a standard tool for biomedical image analysis, supplemented by the TotalSegmentator software capable of delineating more than one hundred anatomic structures in a single scan. The algorithms measured the cross-sectional areas of subcutaneous adipose tissue, the fat layer beneath the skin, and visceral adipose tissue, the fat packed around internal organs, at the level of the third and fourth lumbar vertebrae, a standard landmark in body composition research.

The technical rationale for this approach is straightforward. Body mass index cannot distinguish between fat stored under the skin and fat stored deep within the abdomen, yet these two depots behave in profoundly different ways biologically. Subcutaneous adipose tissue acts largely as a passive energy reservoir and, in some contexts, appears metabolically protective, sequestering lipids away from the liver, muscle, and bloodstream. Visceral adipose tissue, by contrast, drains directly into the portal circulation, is richly innervated and hormonally active, and is strongly associated with insulin resistance, systemic inflammation, and adverse outcomes across a range of acute and chronic illnesses. The idea that these depots might carry opposite prognostic signals during sepsis is not new, but measuring them reliably has traditionally required painstaking manual tracing of CT images, which is impractical at scale.

Among the 1,107 patients in the cohort, 300, or 27.1 percent, died within 28 days of their sepsis diagnosis during the index hospitalization. When the researchers fed their imaging-derived measurements into Cox proportional hazards models adjusted for clinically selected covariates, a clear and internally consistent picture emerged. Greater subcutaneous adipose tissue area was associated with lower mortality, with an adjusted hazard ratio of 0.83 per one standard deviation increase, a statistically significant protective association. Obesity itself, defined here as a body mass index of 25 kilograms per square meter or higher in keeping with thresholds commonly used in Asian populations, was also associated with lower mortality, with an adjusted hazard ratio of 0.62. But the most telling variable was the ratio of visceral to subcutaneous fat: patients with a higher VAT/SAT ratio had significantly higher mortality, with an adjusted hazard ratio of 1.14 per standard deviation increase.

That pattern reframes the obesity paradox in mechanistic terms. It suggests that what has appeared to be a survival advantage of obesity in sepsis may actually reflect the composition of body fat rather than its total quantity. A patient whose excess weight is dominated by subcutaneous fat may be metabolically better buffered against the catabolic storm of critical illness than a leaner patient whose fat is disproportionately visceral. The finding aligns with a growing body of work. A 2016 study in Critical Care Medicine by Pisitsak and colleagues found that an increased visceral-to-subcutaneous adipose tissue ratio in septic patients was associated with adverse outcomes, and subsequent research suggested that the survival benefit of a low ratio depends on the balance of LDL cholesterol clearance versus production during infection. Population-level analyses in the UK Biobank have similarly shown that abdominal fat distribution outperforms traditional anthropometric indices in predicting sepsis outcomes.

The stratified analyses added further texture, though with appropriate statistical caution. In exploratory models stratified by body mass index category, the protective association of subcutaneous fat was most pronounced among underweight patients, where greater subcutaneous adipose tissue area carried an adjusted hazard ratio of 0.37, meaning a substantially lower hazard of death. Conversely, among patients with obesity, a higher visceral-to-subcutaneous ratio was associated with a markedly elevated mortality risk, with an adjusted hazard ratio of 1.48. In other words, not all obesity is created equal: a patient with obesity whose fat is predominantly subcutaneous may carry a very different prognosis from one whose obesity is visceral-dominant. The authors were careful to note, however, that formal interaction tests between these imaging measures and body mass index category did not reach statistical significance, with P values of 0.145 and 0.127, meaning the apparent effect modification could reflect chance and requires confirmation in larger, independent cohorts.

The study also interrogated skeletal muscle, a dimension of body composition that has gained increasing attention in critical care. Sarcopenia, the loss of muscle mass and function, is common in critically ill patients and has been linked to worse long-term outcomes, partly because sepsis itself induces profound muscle wasting through disrupted autophagy and mitochondrial dysfunction. The team quantified psoas muscle measures at the same lumbar level, including the psoas muscle index, a conventional marker of muscle quantity. Strikingly, muscle size itself did not retain an independent association with mortality after adjustment. What did survive the statistical scrutiny was muscle quality: a higher proportion of low-attenuation muscle, which reflects fatty infiltration of the muscle and is a radiographic signature of myosteatosis, was associated with higher mortality, with an adjusted hazard ratio of 1.14. A joint phenotype combining a high visceral-to-subcutaneous ratio with a low psoas muscle index, which the investigators had hypothesized might identify particularly high-risk patients, was not significant after adjustment.

These findings carry real implications for how risk is characterized in the intensive care unit. Abdominal CT scans are already obtained routinely in many sepsis patients to search for the infectious source, meaning the raw imaging data needed for automated body composition analysis often exists before anyone thinks to use it prognostically. A pretrained deep learning pipeline can extract these measurements in seconds without manual labor, and the underlying software is publicly available, making the approach reproducible and potentially deployable as a clinical decision-support tool. If validated externally, a VAT/SAT ratio or a low-attenuation muscle fraction could complement, and in some cases correct, the crude signal provided by body mass index, helping clinicians identify high-risk patients who would be missed by conventional anthropometry, including visceral-dominant patients with obesity and sarcopenic patients of normal weight.

The authors and independent commentators are quick to emphasize the study’s limitations. It was a single-center, retrospective cohort, which raises the possibility of selection bias, since only patients who happened to receive abdominal CT imaging could be included. The subgroup findings, however compelling, rest on exploratory analyses with non-significant interaction tests, and the skeletal muscle results in particular require external validation before they can inform practice. Residual confounding by illness severity, nutritional status, and chronic disease cannot be excluded in any observational design. Still, the convergence of this work with prior mechanistic and epidemiological evidence, and the elegance of using artificial intelligence to turn diagnostic scans that already exist into prognostic information that costs nothing extra, marks a meaningful step forward. The obesity paradox in sepsis has long been an embarrassment to simple models of body size and disease; deep learning analysis of where the body stores its fat may finally explain what the scale never could.

Subject of Research: Deep learning–based CT analysis of abdominal fat distribution and its association with 28-day mortality in sepsis patients

Article Title: Deep learning–derived abdominal adiposity phenotypes and 28-day mortality in sepsis

Article References: Yeo, H. J., Kim, H. L., Kim, K., Jang, J. H., Choi, E., Seol, H. Y., Lee, S. E., & Cho, W. H. (2026). Deep learning–derived abdominal adiposity phenotypes and 28-day mortality in sepsis. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02220-1

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02220-1

Keywords: sepsis, obesity paradox, visceral adipose tissue, subcutaneous adipose tissue, deep learning, nnU-Net, body composition, computed tomography, 28-day mortality, psoas muscle, myosteatosis, critical care

The phenomenon at the centre of the study is known as browning. White adipose tissue is primarily a storage organ, packing energy into a single large lipid droplet per cell. Under certain conditions, however, white fat depots recruit or generate beige adipocytes, cells enriched with mitochondria and with uncoupling protein 1, or UCP1, a molecule that dissipates the mitochondrial proton gradient as heat rather than capturing the energy as ATP. Browning is normally driven by cold exposure or by beta-adrenergic signalling, the same sympathetic pathway that activates classical brown fat. When beige adipogenesis works well, the body burns more fuel and stores less fat. When it fails, visceral fat expands and metabolic disease tends to follow.

Using male mice, the researchers found that stimulating beta-adrenergic receptors with the drug CL316,243, or exposing animals to cold, unexpectedly triggered an influx of neutrophils into epididymal white adipose tissue, a visceral fat depot, but not into subcutaneous fat or brown fat. These infiltrating neutrophils carried activated neutrophil elastase and proteinase 3, enzymes stored in granules and released during inflammation. At the same time that the tissue was being instructed to brown, the arriving neutrophils were deploying proteases that shut the process down. The team showed that when neutrophil elastase was genetically deleted, or when the enzyme was blocked locally within the fat pad using sivelestat, an approved neutrophil elastase inhibitor, browning of visceral fat in response to adrenergic stimulation was substantially rescued, and UCP1 protein levels rose.

The mechanistic work went several layers deep. First, the proteases acted on beige adipocyte precursors, the progenitor cells from which new beige fat cells arise. Neutrophil elastase and proteinase 3 suppressed the proliferation of these precursors by downregulating CDK4 and cyclin D1, two core components of the cell cycle machinery that drive the G1 to S phase transition. With those drivers suppressed, precursor cells became arrested, reducing the pool of cells available for commitment to the beige lineage. This matters because de novo recruitment of beige adipocytes from progenitors, rather than mere activation of pre-existing cells, is a major route through which visceral fat gains thermogenic capacity during cold adaptation.

Second, the enzymes interfered with the differentiation programme itself. The researchers identified insulin-like growth factor binding protein 3, or IGFBP-3, as a critical substrate. IGFBP-3 supports beige adipocyte differentiation, and the neutrophil proteases cleaved it, degrading the factor and thereby weakening the differentiation signal. Prior literature had established that neutrophil elastase and proteinase 3 can function as IGFBP proteases in inflammatory settings, and the new work places that degradative activity squarely within fat tissue biology, linking it to impaired beige adipogenesis. When protease activity was inhibited, IGFBP-3 was preserved and differentiation proceeded more effectively.

Third, the study revealed an indirect route of inhibition. Neutrophil-derived proteases promoted the polarization of adipose tissue macrophages toward the M1, classically inflammatory phenotype. M1 macrophages secrete pro-inflammatory cytokines that are known to suppress thermogenic gene expression and to antagonize the type 2 immune signals, including eosinophil-derived interleukins and M2 macrophage activity, that normally support beige fat development. By tipping the macrophage balance toward inflammation, neutrophils created a tissue environment hostile to thermogenic adipocyte formation, compounding their direct effects on precursors and differentiation.

Importantly, the findings were not confined to mouse models. Analysis of publicly available single-cell RNA sequencing datasets from human adipose tissue revealed elevated expression of ELANE, the gene encoding neutrophil elastase, and PRTN3, the gene encoding proteinase 3, in visceral fat of individuals with obesity, particularly those with type 2 diabetes, compared with subcutaneous fat. Conversely, IGFBP3 expression in adipocytes showed correlations consistent with the proteolytic pathway identified in mice. In laboratory cultures, recombinant human neutrophil elastase and proteinase 3 suppressed the proliferation of human visceral preadipocytes, arrested their cell cycle, and impaired their differentiation into beige adipocytes, mirroring the murine results at the level of human cells.

The therapeutic implications emerged from experiments in mice fed a high-fat diet. Long-term feeding sustained neutrophil infiltration specifically in epididymal visceral fat over ten months. When diet-induced obese mice received sivelestat, the drug suppressed neutrophil activity, enhanced cold-induced browning of visceral fat, decreased visceral fat content, and increased energy expenditure. Sivelestat is already clinically validated for other indications, having been developed and used as a neutrophil elastase inhibitor for acute lung injury and acute respiratory distress syndrome, notably in Japan and in experimental protocols for COVID-19-related lung damage. The prospect of repurposing an existing, safety-characterized drug for obesity treatment is precisely the kind of translational shortcut that draws attention in metabolic medicine, although the authors and the field will recognize that mouse-to-human translation in adipose biology is notoriously fraught, and that sex differences in both browning and neutrophil behaviour, documented in this study and in prior work, complicate extrapolation.

What makes the study conceptually striking is the reversal of expectations. Earlier research had emphasized destructive roles of neutrophils in adipose tissue, including elastase-driven insulin resistance described by Talukdar and colleagues in 2012, and more recent work has even suggested neutrophils help preserve energy stores in activated fat. The new findings position neutrophils as active gatekeepers of adipose plasticity, dynamically throttling the tissue’s thermogenic capacity exactly when sympathetic signals demand it. Whether this represents an evolutionary trade-off, dampening energy expenditure during inflammatory stress, or a maladaptive modern interaction between chronic low-grade inflammation of obesity and an ancient immune programme, remains an open question. What is clear is that the protease activity provides a concrete, druggable point of intervention in a pathway previously managed only through diffuse targets such as sympathetic stimulation, which carries cardiovascular side effects in humans.

The work also refines the emerging picture of immune-metabolic crosstalk in fat. Eosinophils, M2 macrophages, and type 2 cytokines have been shown to promote beige fat; sympathetic neuron-associated macrophages can do the opposite by consuming norepinephrine. Neutrophils and their serine proteases now join this cast, with a mechanism that operates at three levels at once: cell cycle arrest of progenitors, proteolytic destruction of a differentiation factor, and inflammatory remodelling of the macrophage landscape. For the millions of people carrying metabolically harmful visceral fat, the study suggests that taming neutrophil elastase could, in principle, unlock the fat-burning potential already latent within their tissue, and it hands researchers a precise molecular target with which to test that proposition in the clinic.

Subject of Research: How neutrophil serine proteases inhibit thermogenic browning of visceral white adipose tissue

Article Title: Neutrophil serine proteases inhibit thermogenic capacity of visceral white adipose tissue

Article References: Yuan, L., Wu, X., Zong, J., Jiang, M., Gao, S., Zhang, Z., Huang, X., Zhu, M., Xiang, M., Wang, L., Ping, Z., Pan, Y., Ye, D., Xu, A., & Hoo, R. L. C. (2026). Neutrophil serine proteases inhibit thermogenic capacity of visceral white adipose tissue. Nature Metabolism. https://doi.org/10.1038/s42255-026-01598-6

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01598-6

Keywords: neutrophils, neutrophil elastase, proteinase 3, visceral adipose tissue, fat browning, beige adipocytes, thermogenesis, UCP1, obesity, sivelestat, IGFBP-3, macrophage polarization

Adipose tissue in mammals is broadly divided into subcutaneous depots, found under the skin, and visceral depots, which pad the abdominal organs. Although both store energy in the form of lipid droplets, they differ dramatically in their behavior and their consequences for health. Subcutaneous fat is comparatively benign and can undergo thermogenic remodeling, a process in which ordinary white adipocytes acquire features of brown fat cells, becoming packed with mitochondria that burn fuel to produce heat. Visceral fat, by contrast, resists this transformation, known as beiging, and instead tends to enlarge, release fatty acids into the portal circulation, and secrete inflammatory signals that promote insulin resistance. Why visceral fat refuses to beige has long been an open question.

The concept of beiging itself has a rich experimental history. Work from several laboratories over the past two decades, including studies by Rosenwald and colleagues and by Chitraju and colleagues, established that cold exposure and sympathetic nervous system activation recruit new adipocyte precursors in subcutaneous fat that differentiate into thermogenically competent beige adipocytes. Drugs such as beta-adrenergic agonists can induce similar remodeling. Yet when researchers apply the same stimuli to visceral depots, the response is muted or absent. Yuan and colleagues set out to identify what actively enforces this depot specificity, suspecting that the local tissue microenvironment, rather than an intrinsic defect in visceral adipocyte precursors, might be responsible.

The investigative trail led the researchers to neutrophils, the most abundant white blood cells in the human body and classic first responders to infection. Neutrophils are armed with an arsenal of serine proteases, including neutrophil elastase, proteinase 3, and cathepsin G, which they normally deploy to destroy pathogens and remodel extracellular matrix. Earlier work had already implicated neutrophil enzymes in metabolic regulation: Talukdar and colleagues showed in 2012 that neutrophil elastase deficiency protects mice from obesity-associated insulin resistance, and Mansuy-Aubert and colleagues demonstrated in 2013 that neutrophils modulate insulin sensitivity in adipose tissue. What remained unknown was whether these proteases could gate a specific developmental program within fat tissue.

Yuan and colleagues now show that they can. In their model, serine proteases released by neutrophils that reside in or traffic to visceral fat cleave key signaling components required for the beiging program, effectively putting the brakes on thermogenic differentiation before it can begin. When the researchers depleted neutrophils or blocked their proteases, visceral adipose tissue regained some capacity for beiging, acquiring multilocular lipid droplets, elevated mitochondrial content, and increased expression of thermogenic genes. The effect was depot-specific: subcutaneous fat, which hosts fewer of these protease-releasing neutrophils under resting conditions, was largely unaffected, providing a mechanistic explanation for the natural dichotomy between the two depots.

The technical logic of the study is notable for the way it integrates cellular, molecular, and physiological levels of analysis. Single-cell and population-level transcriptomic profiling allowed the authors to map the immune composition of visceral versus subcutaneous depots and to quantify the enrichment of neutrophil signatures and protease transcripts in visceral fat. Genetic and pharmacological perturbations, including protease-deficient models and pharmacologic inhibitors of the sort previously characterized by Korkmaz and colleagues in their comprehensive pharmacological reviews of neutrophil serine proteases, established causality rather than mere correlation. Functional readouts of thermogenesis, including respiratory measurements and gene expression panels anchored on canonical markers such as Ucp1, confirmed that the histological and molecular shifts translated into genuine changes in adipose tissue function.

Why would the body actively suppress heat production in its visceral fat? The authors and the commentary authors offer several evolutionary and physiological interpretations. Thermogenesis is metabolically expensive, and skeletal and cardiac muscle plus brown fat already serve as principal heat-generating organs during cold defense. Restricting beiging to subcutaneous depots may allow the body to preserve the mechanical and structural integrity of visceral fat, which cushions organs, while avoiding the wasteful combustion of a fuel depot located in the abdominal cavity. At the same time, neutrophils are recruited in greater numbers to visceral fat during obesity, as demonstrated classically by Weisberg and Xu and their colleagues in 2003, suggesting that a system designed to restrain thermogenesis in lean animals may become maladaptive when inflammation drives excessive neutrophil accumulation and further locks visceral fat into an metabolically unfavorable state.

The translational implications are considerable. Pharmacological strategies to induce beiging have struggled precisely because systemically administered thermogenic stimuli produce off-target effects, particularly on the cardiovascular system, through beta-adrenergic activation. A pathway that actively suppresses beiging in one specific depot offers an alternative therapeutic logic: relieve the brake rather than press the accelerator. If neutrophil serine protease activity in visceral fat could be selectively inhibited, patients with obesity or type 2 diabetes might regain some of the thermogenic and insulin-sensitizing capacity that their subcutaneous fat already possesses. Protease inhibitors exist for related enzymes, and neutrophil elastase inhibitors have been tested in inflammatory lung disease, providing a medicinal chemistry starting point, although the challenge of targeting protease activity specifically within visceral adipose tissue without impairing antimicrobial immunity remains substantial.

The study also carries conceptual weight for immunometabolism as a field. Over the past two decades, adipose tissue macrophages and T cells have been established as central players in obesity-associated inflammation, following foundational observations linking immune infiltration to metabolic dysfunction in fat. Neutrophils, by contrast, were long treated as short-lived, terminally differentiated cells with narrow antimicrobial functions. The new work joins a growing body of evidence, including the 2026 study by Son and colleagues in Nature on neutrophil heterogeneity, that neutrophils are functionally versatile cells whose granule contents can reprogram the behavior of surrounding tissues. Tol and Stienstra emphasize in their commentary that the identification of protease-gated depot specificity fundamentally reframes neutrophils as custodians of adipose tissue identity, not merely as inflammatory mercenaries.

Important questions remain. The precise molecular targets of the proteases within the beiging pathway, whether they act on adipocyte precursors directly, on extracellular matrix cues, or on paracrine signals from other stromal cells, will require further dissection. It is also unclear whether chronic pharmacological inhibition of these enzymes in adult animals produces durable, safe increases in visceral thermogenesis, or whether the brake exists to prevent pathology of its own. Human relevance, as always in mouse-first immunometabolism, must be established: visceral fat biopsies from people with varying degrees of obesity and metabolic health could test whether neutrophil protease abundance correlates with impaired beiging capacity in our own species. Nevertheless, by identifying a concrete, druggable class of enzymes that explains why visceral fat refuses to become a furnace, Yuan and colleagues have converted a long-standing observational puzzle into a tractable therapeutic opportunity, and have added an unexpected chapter to the story of how the immune system writes the metabolic rules of our bodies.

Subject of Research: Depot-specific suppression of visceral fat beiging by neutrophil-derived serine proteases

Article Title: Neutrophil proteases put the brakes on visceral beiging

Article References: Tol, M. J., & Stienstra, R. (2026). Neutrophil proteases put the brakes on visceral beiging. Nature Metabolism. https://doi.org/10.1038/s42255-026-01606-9

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01606-9

Keywords: neutrophils, serine proteases, visceral adipose tissue, beiging, thermogenesis, immunometabolism, obesity, insulin resistance, adipose tissue plasticity, innate immune cells, metabolism, Neutrophil

For decades, BMI has been the primary clinical tool for gauging obesity-related health risks, relying essentially on external body measurements. However, BMI fails to account for where fat is distributed across the body. This study reveals that fat stored in the visceral compartment—surrounding vital organs—and fat accumulated within the liver play a far more insidious role in predisposing individuals to vascular pathologies than previously realized. Unlike subcutaneous fat, visceral and liver fat are metabolically dynamic, secreting pro-inflammatory molecules and lipid byproducts that accelerate vascular injury.

Utilizing sophisticated magnetic resonance imaging (MRI) techniques, researchers performed an extensive analysis of fat distribution patterns coupled with vascular assessments of over 33,000 middle-aged adults enrolled in two large cohort studies: the Canadian Alliance for Healthy Hearts and Minds (CAHHM) and the UK Biobank. These imaging datasets permitted precise quantification of visceral fat deposits and hepatic steatosis alongside detailed characterization of carotid artery health, specifically focusing on carotid intima-media thickness and plaque accumulation—key indicators of atherosclerotic cardiovascular disease.

The results were stark: an unequivocal association emerged linking increased visceral fat volumes with thickening and plaque development in the carotid arteries. These arteries, vital conduits supplying oxygenated blood to the brain, exhibited changes indicative of early atherosclerosis. Hepatic fat, while showing a somewhat weaker correlation, also independently contributed to vascular degeneration. Crucially, these associations persisted even after adjusting for traditional cardiovascular risk variables such as cholesterol levels, blood pressure, glucose metabolism, and lifestyle factors, underscoring the unique and direct impact of these fat depots on arterial health.

Dr. Russell de Souza, co-lead author and associate professor at McMaster’s Department of Health Research Methods, Evidence, and Impact, emphasized that such findings disrupt previous assumptions which primarily confined adiposity risk assessments to external body measures. “Our data indicate that hidden fat reserves are stealthily contributing to arterial injury, undetected by standard obesity metrics,” Dr. de Souza highlighted. This phenomenon implies that many individuals deemed ‘healthy’ or ‘normal weight’ by BMI standards may still harbor heightened cardiovascular risk due to their internal fat composition.

Further elucidating these insights, vascular medicine expert Dr. Sonia Anand, corresponding author and professor at McMaster’s Department of Medicine, remarked on the metabolic activity of these fat stores. Unlike inert tissue, visceral and hepatic adipose tissues are hormonally active and release substances that promote systemic inflammation, endothelial dysfunction, and oxidative stress—pathophysiological processes central to atherosclerosis. This biochemical assault occurs silently, even among those without overt obesity signs, reframing how clinicians might strategize risk evaluations.

The methodological rigor underpinning this research rested on integrating large-scale epidemiological cohorts with advanced imaging modalities. The MRI scans provided unparalleled clarity, enabling differentiation between subcutaneous and deeper fat layers and their vascular consequences. Through complex statistical modeling, the researchers isolated the effects of these fat depots on carotid arterial pathology, confirming their independent contribution beyond lifestyle influences like diet, exercise, and smoking.

These findings compel a paradigm shift in cardiovascular risk assessment. Health professionals are urged to transcend reliance on BMI or waist circumference alone and to incorporate imaging-based evaluations that can detect visceral and hepatic fat accumulation. This approach promises more accurate identification of individuals at elevated risk for heart attack and stroke, facilitating earlier intervention strategies potentially capable of mitigating vascular damage.

Beyond clinical implications, this study strengthens the imperative for public awareness regarding the hidden dangers of visceral and liver fat. Traditional perceptions of health based solely on visible body weight inadequately reflect true cardiovascular risk. The stealth nature of these fat stores demands educational campaigns to enhance understanding of “metabolically obese normal weight” individuals—those whose internal fat burden belies their outward physique.

The supporting infrastructure of this study was multi-institutional and interdisciplinary. Funding and resources were provided by the Canadian Partnership Against Cancer, the Heart and Stroke Foundation of Canada, and the Canadian Institutes of Health Research, among others. Collaborative efforts involved the Population Health Research Institute, Montreal Heart Institute, and Sunnybrook Health Sciences Centre, whose in-kind MRI support and Bayer AG’s IV contrast provisioning were pivotal. Additionally, data from the Canadian Partnership for Tomorrow’s Health and the PURE Study enriched this research framework.

As this landmark study disseminates within the scientific and medical communities, it underscores the imperative to reconsider how obesity and cardiovascular disease are conceptualized and assessed. It is a clarion call for innovation in both clinical diagnostics and preventative medicine, advocating for nuanced biomarkers that unveil the hidden threats lurking beneath the surface.

The revelation that visceral and liver fat contribute significantly to carotid artery disease transforms the landscape of cardiometabolic research. It opens avenues for new therapies aimed at these specific fat depots and presents an urgent need for technological integration of imaging tools in routine clinical settings to better predict and prevent cardiovascular events.

In conclusion, McMaster University’s research crystallizes a profound truth about body fat—a reminder that weight seen externally tells only part of the story. The silent, internal fat within us may well hold the keys to unlocking earlier, life-saving interventions against atherosclerosis and related cardiovascular disorders.

Subject of Research: The impact of visceral adipose tissue and hepatic fat on carotid artery atherosclerosis and cardiovascular risk.

Article Title: Visceral adipose tissue and hepatic fat as determinants of carotid atherosclerosis

News Publication Date: October 17, 2025

Web References:
https://dx.doi.org/10.1038/s43856-025-01123-y

Keywords: Metabolic health, visceral fat, hepatic fat, carotid atherosclerosis, cardiovascular risk, MRI imaging, obesity, inflammation, artery damage, metabolic adipose tissue, cardiovascular disease, fat distribution